immuno-oncology
ALX Oncology’s CD47 Drug Shows Enhanced Response in Solid Tumors, Aiming for Phase 3 Trials
Anika Sharma
ALX Oncology is reevaluating the potential of its anti-CD47 drug in the context of solid tumors, buoyed by promising data. ...
Magrolimab fails to improve survival in leukemia, Gilead halts trial
Anika Sharma
Another failure has occurred in Gilead Sciences’ $4.9 billion immuno-oncology wager. Following an ad hoc analysis of a phase 3 ...
Abpro to go public via SPAC merger with Atlantic Coastal, raising funds for its HER2xCD3 bispecific and COVID-19 program
Anika Sharma
Abpro is making a return to the public market after a five-year hiatus, this time teaming up with Atlantic Coastal ...
